Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?

In 2020, ASCO recommended that all women with epithelial ovarian cancer have germline testing for BRCA1/2 mutations, and those without a germline pathogenic variant (PV) should have somatic tumor testing to determine eligibility for a poly (ADP-ribose) polymerase inhibitor. Consequently, the majorit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Janice S., Tinker, Anna V., Santos, Jennifer, Compton, Katie, Sun, Sophie, Schrader, Kasmintan A., Karsan, Aly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616645/
https://www.ncbi.nlm.nih.gov/pubmed/36265114
http://dx.doi.org/10.1200/PO.22.00033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616645/
https://www.ncbi.nlm.nih.gov/pubmed/36265114
http://dx.doi.org/10.1200/PO.22.00033

Ejemplares similares